Champlain Investment Partners LLC Has $36.42 Million Position in SiBone $SIBN

Key Points

• Champlain Investment Partners LLC reduced its stake in SiBone by 4.6%, selling 125,093 shares and holding 2,595,731 shares, valued at approximately $36.4 million.
• Institutional investors control 98.11% of SiBone's stock, with several hedge funds increasing their positions during the fourth quarter.
• Analysts have given SiBone a consensus rating of "Buy" with a price target averaging $23.67, following recent analyst upgrades.

Champlain Investment Partners LLC decreased its holdings in SiBone (NASDAQ:SIBN - Free Report) by 4.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,595,731 shares of the company's stock after selling 125,093 shares during the period. Champlain Investment Partners LLC owned about 6.09% of SiBone worth $36,418,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in SiBone by 4.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,373 shares of the company's stock worth $328,000 after buying an additional 988 shares during the last quarter. Invesco Ltd. increased its holdings in SiBone by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock worth $241,000 after buying an additional 1,413 shares during the last quarter. Rhumbline Advisers increased its holdings in SiBone by 3.6% in the first quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock worth $838,000 after buying an additional 2,100 shares during the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in SiBone in the first quarter worth approximately $34,000. Finally, Barclays PLC increased its holdings in SiBone by 2.7% in the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock worth $1,391,000 after buying an additional 2,589 shares during the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Insider Buying and Selling

In other SiBone news, insider Anthony J. Recupero sold 3,833 shares of SiBone stock in a transaction on Monday, August 18th. The shares were sold at an average price of $15.62, for a total transaction of $59,871.46. Following the sale, the insider owned 275,288 shares in the company, valued at $4,299,998.56. The trade was a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John Gordon Freund sold 12,132 shares of SiBone stock in a transaction on Friday, August 8th. The stock was sold at an average price of $15.99, for a total transaction of $193,990.68. Following the sale, the director owned 91,767 shares in the company, valued at $1,467,354.33. This represents a 11.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold 49,967 shares of company stock valued at $829,469 in the last ninety days. Company insiders own 4.00% of the company's stock.

SiBone Stock Performance

Shares of SIBN traded up $0.05 during mid-day trading on Friday, hitting $16.67. The company's stock had a trading volume of 197,393 shares, compared to its average volume of 504,886. SiBone has a one year low of $11.70 and a one year high of $20.05. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. The firm has a market capitalization of $719.16 million, a PE ratio of -29.77 and a beta of 0.91. The stock's 50-day moving average is $17.01 and its two-hundred day moving average is $16.51.

SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%.The company had revenue of $48.63 million during the quarter, compared to analysts' expectations of $48.12 million. SiBone has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that SiBone will post -0.78 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on SIBN. Needham & Company LLC restated a "buy" rating and issued a $24.00 price objective on shares of SiBone in a report on Tuesday, May 6th. Cantor Fitzgerald set a $25.00 price target on SiBone and gave the company an "overweight" rating in a report on Monday, August 11th. Truist Financial increased their price target on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Wall Street Zen downgraded SiBone from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $23.67.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.